A Framework for the development and application of biological monitoring guidance values



Similar documents
ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

Section 4. Toxicology

September 19, 1984 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM

Nicotine Testing Common Questions

Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS)

Teacher s Guide. Chemicals & Human Health Website. Toxicology Activity

Module Three. Risk Assessment

The Science of Chemical Safety Essential Toxicology - 4. Hazard and Risk. John Duffus & Howard Worth. IUPAC Educators Resource Material IUPAC

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

Definitions and Interpretations of Skin Notations and the Use of Biological Monitoring to Assess Total Exposure

BIOMARKERS & HUMAN BIOMONITORING

Occupational/Industrial Hygiene Knowledge and Competency Requirements

Risk Assessment for Food Safety in Hong Kong

BIOTECHNOLOGY OPERATIONS

Material Safety Data Sheet 1100/105 Sikkerheds Data Blade (MSDB)

CDC s National Environmental Public Health Tracking Network

A FDA Perspective on Nanomedicine Current Initiatives in the US

Importing pharmaceutical products to China

SYNTHETIC TURF STUDY: OVERVIEW OF THE STUDY ELEMENTS

HAZARD COMMUNICATION: NEW LABEL ELEMENTS AND SAFETY DATA SHEET (SDS) FORMAT

Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency

Environmental Health Traineeship and Fellowship Program

Horizon 2020 Proposal: CAT-APP

Exploring Metabolic Outcomes and Toxic Effects. DiscoveryGate SM Version 1.4 SP2 Workshop Guide

Effects of Welding on Health I

The Facts on Equine Drug Testing

Guidance for Industry

Guidance for Industry Safety Testing of Drug Metabolites

Pharmacology skills for drug discovery. Why is pharmacology important?

Basic Overview of Preclinical Toxicology Animal Models

American Society of Addiction Medicine

MATERIAL SAFETY DATA SHEET COPPER ALLOYS 101, 102, 103, 104, 110, 122, 151, XP5

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

SAFETY DATA SHEET ZANFEL VERSION 1.5.0

8. REGULATIONS AND ADVISORIES

ITRC PROJECT PROPOSAL

AJAX CLEANER POWDER-OXYGEN BLEACH

Basics of Risk Assessment

WHAT IS RISK? Definition: probability of harm or loss Risk = Hazard x Exposure Risk can be voluntary or involuntary Interpretation of risk differs for

Republic. Milena Černá, A. Krsková

Risk Assessment of Pesticides Residue by JMPR - To set ADI and ARfD-

Risk assessment and occupational safety and health protection in construction work on contaminated sites

RHODE ISLAND STATUTES : (4) RHODE ISLAND GENERAL LAWS: TITLE 23: HEALTH AND SAFETY CHAPTER 23-1: DEPARTMENT OF HEALTH

Apply with Resume to: Submenu Path Company/Careers/Current Openings/Job Type: Science

Ramazzini days LT Budnik

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

Frequently asked questions on the procedure for the re-assessment of glyphosate within the framework of the EU active substance review

NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997

Version: 1.0 Revision Date: 06/25/2013 Print Date: 06/25/2013 POOL TIME D.E. FILTER POWDER

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

Uncertainty factors:

General Principles for the Safety Assessment of Excipients

Introduction. MassDEP, Office of Research and Standards 1 Tetrachloroethylene

Biological importance of metabolites. Safety and efficacy aspects

Chemical safety and big data: the industry s demands

Introduction to pharmaceutical technology

CAS-No. EC-No. Index-No. Concentration Controlled Pore Glass May be harmful if inhaled. May cause respiratory tract irritation.

MATERIAL SAFETY DATA SHEET

Material Safety Data Sheet

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training

Update of NIOSH Carcinogen Classification and Target Risk Level Policy for Chemical Hazards in the Workplace

OCCUPATIONAL LUNG CANCER

Human Biomonitoring of Mercury Exposure

2,2,2 trifluoroethanol

19/03/2012 Toxicologicalcharacterizationof PM10: case study Genk-Zuid. R. Van Den Heuvel

WINDEX COMMERCIAL LINE GLASS CLEANER WITH AMMONIA- D

GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

Fuel Oils. Public Health Statement for. June 1995

1. INTRODUCTION 2. GENERAL CONSIDERATIONS

PRODUCT SAFETY DATA SHEET Product name: SOFT LEAD PRODUCTS

4.1 Objectives of Clinical Trial Assessment

Communication of Uncertainty in Hazard & Risk Assessment: Panel Discussion. Lynn H. Pottenger, PhD, DABT The Dow Chemical Company

1. PUBLIC HEALTH STATEMENT

Material Safety Data Sheet

IMPURITIES IN NEW DRUG PRODUCTS

Tungsten Heavy Alloy. Densimet, Mallory Metal, Densalloy, High Density Tungsten Alloy

GPS Safety Summary. Tert-butyl 2-ethylhexaneperoxoate

Hydrogen Sulfide (H 2 S) New issues in U.S. EPA Regulation and Toxicology

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

Industrial Hygiene Program

Environmental Education Associates

Re: GRAS Notice No. AGRN

Introduction to Industrial Hygiene for the Safety Professional

SOFTSOAP LIQUID HAND SOAP LAVENDER & CHAMOMILE

MSDS authored by: : Kemika XXI Inc /15/2006

WINDEX MULTI-SURFACE CLEANER - VINEGAR

In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations

Access to Employee Exposure and Medical Records

SAFETY DATA SHEET FILE NO.: , DRY CIDER VINEGAR SDS DATE: 05/05/15

WINDEX ORIGINAL GLASS CLEANER WITH AMMONIA-D

THRESHOLD OF TOXICOLOGICAL CONCERN (TTC) IN RISK ASSESSMENT

Information for environmental health emergencies: what can WHO offer? Joanna Tempowski International Programme on Chemical Safety (WHO/ILO/UNEP

1 Risk Management relates to the quality or acceptability of the work environment.

Chemical Risk Assessment in Absence of Adequate Toxicological Data

Chapter 7: Effect Modification

BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH PUBLIC HEALTH COMPETENCIES

SIGMA-ALDRICH. Material Safety Data Sheet Version 4.0 Revision Date 02/27/2010 Print Date 08/25/2011

ii. What does P&G think of the EWG's suggestion that cord blood testing be required as part of any chemical assessment process?

SCRUBBING BUBBLES VANISH CONTINUOUS CLEAN DROP- INS

Transcription:

A Framework for the development and application of biological monitoring guidance values Len Levy, Ruth Bevan, Greet Schoeters, Roel Smolders, Juergen Angerer, Ovnair Sepai, Kate Jones & John Cocker Institute of Environment and Health, Cranfield University, UK; Health and Safety Laboratory, UK; Health Protection Agency, UK; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Ruhr University, Germany; Vito, Belgium.

From Hazard to Disease

BM: Requirements Ethics informed consent Why, what, when, how, meaning of results Matrix Blood, urine, saliva, breath etc Analyte Specific, metabolite, related to toxicity, stability, kinetics, dose-response Analytical Method Specific, accurate, precise,

Biological Guidance Values Health-based HBM 1 & 2 (HBM Commission) BEs (Summit Toxicology) BEIs (ACGIH) BATs (MAK/DFG) BLVs (SCOEL) BMGVs(HSE) Non-health-based Reference values BARs (MAK/DFG) BLWs (MAK/DFG) EKAs (MAK/DFG) Good OH practice (90% values) (HSE)

The need for a framework for BMGVs The problem: A need for more BM guidance values A need for more BM data A need to manage the journey from detection to understanding A need to understand the different BMGVs The solution? A framework describing utility and limitations of BM data & guidance values

Method Develop framework criteria Develop Framework Consult Advisory Group & Revise Test framework with model compounds Present Framework at a Workshop Revise & Publish

Expert Advisory Group

A Framework for BMGVs Level 1 Level 2 Level 3 Level 4 Data only Data & Toxicity Toxicity & interest based Probability based Either acceptable (eg clinical range) or unknown Do not exceed, try to reduce Safe level Safe level no adverse outcomes expected If unknown get data on toxicity & health outcomes Get data on sources and toxicology Get epidemiology data to check assumptions No further data needs

Framework Criteria 1 Level 1 Biomonitoring Data only (not health-based) available analytical method for the substance (or its metabolites) detection in a biological fluid (eg. blood and urine) data on toxicity of the substance or the meaning of results is not available. Utility very limited

Framework Criteria 2 Level 2 Biomonitoring data plus some interest (not health-based) Level 1 criteria and: good quality biomonitoring data some reason for concern regarding potential health effects based on hazard information some basic metabolism and toxicokinetic data insufficient data to propose a health-based BGV Examples: Reference Ranges, Control-based occupational BMGVs

Framework Criteria 3 Level 3 Toxicity Data (health-based) Level 2 criteria and: good quality biomonitoring data some reason for concern regarding health effects following exposure good metabolism and toxicokinetic data insufficient data to propose a epidemiology-based BGV. Examples: HBM 1 & 2, BEs, BATs, BEIs, BLVs

Framework Criteria 4 Level 4 Toxicity and probability data (health-based) Level 3 criteria and: good data from epidemiology studies

Testing the Framework Proforma Criteria uses, potential routes of exposure and current health concerns toxicity data, including biological effect monitoring data, if available selection of the most appropriate biomarkers, including information on reference ranges, occupational guidance value, PK or PBPK models, concentration of pure compound or metabolites in blood, urine, environment, inter- and intra-variability analytical methods, including detection limits, reliability, reference materials, external quality assurance, known confounders epidemiology data, including any data linking external exposure with health effect, data linking biological monitoring data with health effects identification of risk management procedures identification of susceptible groups and populations communication issues associated with different types of BGVs

Framework test compounds Level 1: Samarium Level 2 : Cypermethrin, Methyl tert-butyl ether, Platinum Polybrominated diphenyl ethers, TDI Level 3: Acrylamide, Di(2-ethylhexyl) Phthalate Toluene Level 4: Benzene Cadmium Lead

Level 1 data only, non-health based BGV Samarium Few data on toxicity and no published biological monitoring data Low acute toxicity of rare earth metals and samarium chelates used in cancer Occupational exposure to samarium may result in inhalation of dusts with possible development of pneumoconiosis Further work is needed to identify a reference range for samarium and its toxicokinetics

Level 2 non-health based upper limit value Platinum Identified as a potential health hazard due to its omnipresence in the environment. Major routes of uptake and population HBM reference ranges are known Well-validated sensitive analytical techniques available Very little known about associated health effects of exposure

Level 3 Toxicity based BGV Acrylamide Suspected carcinogen in humans Main sources of exposure are food and tobacco smoke Estimation of internal exposure carried out through measurement of the Hb-adduct of AA (AAVal) which reflects the AA dose taken up in the previous 4 months Reference ranges established for AAVal for adults and children Mercapturic acids of AA and GA are main metabolites, which are excreted with urine and represent exposure of the last two days.

Level 4 Toxicity and Probability Based BGV Cadmium Primary pathways for uptake, toxico- and pharmacokinetic properties, and associated health effects extensively validated Reference values and health based HBM-values documented Epidemiological studies have confirmed in vivo and in vitro findings on Cd exposure-dose-response continuum in the general population Analytical methods documented in internationally established standard operation procedures, reference materials available and confounders well known and accounted for Urinary Cd concentrations are an excellent biomarker to describe exposure to Cd and can directly be related to associated health effects.

Summary Table Test Chemical Framework Element Level Exposure: Toxicity: Biomarkers: Analytical: Epidemiology: Risk Groups: General Toxicokinetics Reference Detection Link between Management: Defined susceptible Population (inc half-life) ranges limits exposure and Exposure groups Susceptible Group(s) Dose-response relationship Occupational guidance Ref materials / QA scheme human health effect reduction measures Inter- and intraindividual variability Samarium Main metabolite(s) values PK / PBPK models Confounders Link between BM data and health effect 1 _ Platinum 2 Acrylamide 3 Cadmium 4

Conclusions The framework: Suggests 4 levels for different types of BMGV Levels are based on available data for hazard, exposure and risk Suggests minimum data requirements Helps to understand the different types of BMGVs and their limitations Helps with communication of BM results Helps to manage the journey

Next Steps Publish a peer-reviewed paper Make full report available on Cefic-LRI website Encourage other BM groups to test and refine this framework to fully assess utility Although not intended for regulatory purposes the framework might assist regulators who need to underpin their processes

Acknowledgements Members of the Advisory Group Holger Koch - for help with DEHP and workshop Funding by CEFIC LRI-HBM1-UCRA-0712